What Happens During a Renal Mass Biopsy for Fat-Poor AML?

If your imaging suggests a fat-poor angiomyolipoma (a kidney tumor with very little fat), your doctor may recommend a renal mass biopsy. Because fat-poor angiomyolipomas can look very similar to renal cell carcinoma (kidney cancer) on scans, getting a tissue sample can provide important information to help distinguish between the two and guide your treatment ^[1].

During a renal mass biopsy, a doctor uses imaging to guide a thin needle into the kidney tumor and removes small pieces of tissue for testing ^[2]. While biopsy is a highly useful tool, it is not infallible; a small sample may not capture the whole tumor, so results are always interpreted alongside your imaging ^[3].

Preparing for the Biopsy

Before the procedure, your care team will evaluate your risk for bleeding ^[4]. They will check your bloodwork, including your platelet count and your INR (a measure of how long it takes your blood to clot) ^[4].

You will need to discuss all the medications and supplements you take, especially blood thinners, anti-inflammatories, or aspirin. Do not stop taking any prescribed blood thinners on your own, as this can increase your risk of dangerous blood clots. Your biopsy team will coordinate with your prescribing doctor to give you an individualized plan for pausing and restarting these medications ^[4].

If your doctor plans to use intravenous (IV) sedation to help you relax, you may be asked to fast before the procedure and you will need a responsible adult to drive you home.

The Procedure: What to Expect

A renal mass biopsy is typically an outpatient procedure performed by an interventional radiologist. Here is what generally happens:

• Positioning and Comfort: You will likely lie on your stomach or side. The team will clean the skin and inject a local anesthetic to numb the area ^[2]. You may feel a brief sting or burn, followed by pressure. If you are receiving IV sedation, you will feel relaxed and sleepy.
• Imaging Guidance: The doctor will use an ultrasound or a CT scan to see the tumor in real-time and carefully target the lesion ^[2].
• Taking the Samples: The doctor will use a specialized “core-needle” device to remove tiny, solid cylinders of tissue ^[2]. Taking multiple cores gives the pathologist a better chance of making a confident diagnosis ^[5]. You might hear a clicking sound as the samples are taken.

Recovery and Safety

After the biopsy, you will be monitored in a recovery area, typically for a few hours, to ensure you are not having any immediate bleeding complications ^[6]. You will be given specific instructions on activity restrictions, such as avoiding heavy lifting for a few days.

Renal mass biopsies are generally safe. Based on studies of kidney biopsies, severe complications are rare, but risks include:

• Soreness and Pain: Mild soreness at the site is common. Clinically significant pain is rare (seen in roughly 1% of patients in some studies) ^[7].
• Bleeding: A small collection of blood around the kidney (hematoma) may occur in about 5% of cases ^[7][8]. Severe bleeding that requires a transfusion or further procedures is very rare (less than 1%) ^[7][3].
• Infection: Kidney infections are very uncommon, occurring in roughly 0.5% of cases ^[8].

When to Seek Immediate Medical Attention:
Most patients recover smoothly, but you should call your doctor or go to the nearest emergency department if you experience any of the following after you go home:

• Worsening or severe pain in your back, flank, or abdomen
• Persistent bright-red blood or large clots in your urine
• Dizziness, fainting, or marked weakness
• Fever or chills
• Difficulty urinating or shortness of breath

The Pathology Report

The removed tissue is sent to a pathologist. Classic angiomyolipomas have a mix of blood vessels, smooth muscle, and fat ^[9]. However, a fat-poor angiomyolipoma lacks typical fatty tissue and can look like kidney cancer under the microscope ^[10].

To help tell the difference, the pathologist uses immunohistochemistry—special tests that use antibodies to identify specific proteins in the cells ^[11].

• HMB-45 and Melan-A: These markers are often present in angiomyolipomas but typically not in kidney cancers ^[12][11].
• Smooth Muscle Actin (SMA): This marker can highlight the smooth muscle component of the tumor ^[11].

These markers are supportive tools, not guaranteed yes-or-no tests. The pathologist combines the marker results, the tissue’s physical appearance, and your imaging scans to reach a diagnosis ^[10][13].

How the Results Change Your Plan

Your care team will review the pathology report alongside your imaging to determine the next steps. Possible outcomes include:

1. Confirmation of a Benign Angiomyolipoma: If the biopsy confirms a classic fat-poor angiomyolipoma, the tumor is generally considered benign ^[1]. For small, asymptomatic masses, doctors often recommend active surveillance (regular monitoring with scans) ^[14]. Note that rare subtypes, like epithelioid angiomyolipoma, can have less predictable behavior and may require specialized review or treatment ^[10].
2. Diagnosis of Kidney Cancer: If the sample shows renal cell carcinoma, treatment options will depend on the tumor’s size, stage, and your overall health. Options may include active surveillance (for certain small tumors), surgery to remove part or all of the kidney, or thermal ablation (using heat or cold to destroy the tumor) ^[14][15].
3. Other or Indeterminate Results: The biopsy might reveal a different type of benign tumor, a different kidney issue, or tissue that cannot be clearly classified, which may require a review by a specialized genitourinary pathologist.
4. Nondiagnostic Result: In about 9% to 15% of cases, the biopsy does not retrieve enough abnormal tissue to make a diagnosis ^[16]. This is more common with smaller or harder-to-reach tumors ^[17]. A nondiagnostic result does not mean the tumor is benign ^[18]. If this happens, your doctor will not automatically recommend surgery; instead, options may include a repeat biopsy (which studies show is often successful), expert multidisciplinary review, close imaging surveillance, or, if clinical suspicion remains very high, treatment ^[7][18].